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INTRODUCTION 
 
 
 
          Venous thrombo embolism [VTE] is a frequent cause of 
preventable illness and death in hospitalized patients. 25% of all cases 
of venous thrombo embolism are associated with hospitalization and 
50 to 75% of cases of VTE in hospitalized patients occur on those in 
medical wards. 
    
 
In general, detection of deep vein thrombosis [DVT] in  
hospitalized patients not on thromboprophylaxis by venography is 
10.5% to  14.9% 1 and by ultrasound venous Doppler is 5% 2 
.Thrombosis was asymptomatic in 70%  of cases. Pulmonary 
embolism occurred in   0.3 to 1.5 % of cases and proximal DVT in 2 
to 4.9%. PE accounts for 5 to 10 % of  deaths in hospitalized patients.  
 
 
In   One meta analysis of four studies of 5256 patients with 
DVT as end point and 5 studies of 7355 patients with death as end 
point and 9 studies of 19,958 patients with pulmonary embolism as 
end point anticoagulation decreased relative risk of pulmonary 
embolism [0.43;  95% CI  0.26- 0.71] and fatal pulmonary embolism 
[0.38; 95% CI 0.21 - 0.69] and non significant relative risk of  DVT  [ 
0.47; 95% CI  0.77 – 1.00 ] with no effect on overall mortality and non 
significant increase in relative risk of bleed [1.32; 95% CI 0.73 to 2.37 
]3 
 
Three randomized control trials with Enoxaparin  [MEDENOX] 
p<0.001, the prospective evaluation of Dalteparin efficacy  for 
prevention of VTE in immobilized patients trial [PREVENT] p=0.002, 
Arixtra for thromboembolism prevention in medical indication study 
[ARTEMIS] p = 0.03] using fondaparinux were done to assess the use 
of  anticoagulation routinely in all immobilized patients. The end point 
was the presence of asymptomatic distal thrombi diagnosed by means 
of screening venography. The presence of DVT was found in 60% of 
the stroke patients thus stressing the use of routine anticoagulation in 
patients with extremity paresis or paralysis 4 
                    
Analysis of data from IST , international stroke trial allows a 
comparison of the effect of medium dose heparin [12,500 U of UFH 
twice daily]  initiated within 48 hrs of ischemic stroke and continued 
for two weeks to no heparin on a number of end points. Although this 
dosing regimen reduced the risk of PE and recurrent ischemic stroke , 
the reduction was more than offset by an increased risk of  emorrhagic 
transformation and extra cranial hemorrhage. Overall there was an 
increased risk of death and or recurrent stroke  and major non fatal 
extra cranial bleeds of 0.5% and 1.5% respectively during the 
treatment period.5  
 
White et.al studied the risk of warfarin related complications in 
22,000 unselected group with subgroup of 1312 patients with h/o 
stroke, the readmission rate due to bleeding was 1.7%.The excess risk 
of intracranial hemorrhage in this subgroup was not specifically 
studied, though it was 0.1% in the group as a whole. 6 
 
AREAS OF UNCERTAINITY: 
                     
There is strong evidence from well conducted  clinical trials that 
anticoagulation prophylaxis reduces the risk of asymptomatic DVT 
and proximal DVT. Less information is available regarding effects on 
improved outcomes in terms of fatal and non fatal pulmonary 
embolism.                  
                 
Because entry into trials is mainly by patients in high risk group 
less information is  available in a general hospital population. Further, 
trials are mostly done on surgical patients the end information cannot 
be applied to patients in general medical wards with comorbid 
conditions and especially stroke patients where the risk of bleeding 
should be weighed against prophylaxis for thromboembolism. 
               
There is no consensual opinion available about the best  
prophylactic method for DVT. 
 
 
AIMS OF THE STUDY: 
     
 
With this background study was conducted to find out  
 
 
 
• Prevalence of Deep vein thrombosis in patients admitted 
with acute stroke. 
 
• The need for routine anticoagulation for prophylaxis against 
DVT in acute stroke patients 
 
 
 
                           REVIEW OF LITERATURE 
 
 
Stroke ranks second after ischemic heart disease as a cause of 
lost disability adjusted – life years in high income countries and as a 
cause of death worldwide. 7 The incidence of stroke varies among 
countries and increases exponentially with age. In  western societies, 
about 80% of strokes are caused by focal cerebral ischemia due to 
arterial occlusion and the remaining 20% are caused by hemorrhages.8 
 
  
Venous thromboembolism[VTE] is a common potentially life 
threatening complication that incorporates signs and symptoms of two 
inter-related but distinct clinical conditions, deep vein thrombosis 
[DVT] and pulmonary embolism [PE];this is often a silent yet 
potentially fatal disease. When symptoms do occur ,they are non-
specific and the first manifestation may be fatal PE. Long term 
morbidity is a consequence of VTE since unrecognized and untreated 
thrombo- embolic episodes predispose  patients to recurrent events. 
 
 
 
 
 
 
 
 
INCIDENCE OF DEEP VEIN THROMBOSIS AFTER 
STROKE: 
Studies with I -125     fibrinogen screening in patients with acute 
hemiplegic stroke have shown an incidence of DVT  of approximately 
50% within two weeks in absence of heparin prophylaxis.The majority 
of these affect the paralysed leg and are asymptomatic.9  
 
Approximately two thirds of these are below knee DVTs ,10 in 
contrast to unselected [non-stroke]  patients presenting with 
symptomatic DVT, in whom majority are proximal.11 
          
DVTs develop as early as 2nd  day with peak incidence between 
days 2 and 7. The risk of  DVT correlates with degree of paralysis 12 
and is greater in older patients13 as well as those with AF14.  
 
Predeliction for paralysed leg is probably explained by loss of 
calf muscle pump and repeated minor trauma.15 
 
          DVT  is also present in significant proportion of  patients during 
rehabilitation phase of stroke, the risk being more in those who are 
immobile. In one study of 150 patients admitted in stroke 
rehabilitation unit, at an average, 9 weeks after stroke, bilateral 
venography  revealed DVT in 33% 16. 
 
CLINICAL SIGNIFICANCE  OF ASYMPTOMATIC 
PROXIMAL DVT AFTER STROKE: 
 
The main clinical significance of asymptomatic proximal DVT  
is its potential to cause fatal pulmonary embolism. Indeed, the 
majority of symptomatic PEs are unheralded and arise from previously 
subclinical DVT.17 
 
In a study of unselected patients performed before 
anticoagulants were in routine use, untreated, clinically apparent DVT 
was associated with a mortality from PE of up to 37%.18 The risk of 
fatal PE associated with untreated  subclinical DVT is lower , though 
it remains significant. A recent overview in post operative patients  
has suggested that predominantly subclinical DVT diagnosed by I 125 
fibrinogen scanning is associated with 5% risk of fatal PE19 20.  
 
Although there are few data on natural history of untreated 
subclinical DVT in stroke patients, in one study patients with proximal 
subclinical DVT had a 35% risk of clinical PE.21 
  
Fatal PE usually arise from proximal DVT22.3% of stroke 
patients succumb to PE in 3 months 23, a mortality confined to those 
who develop DVT. Because one third of of these are proximal and 
most are silent, the data suggest that the mortality associated with 
untreated proximal subclinical  DVT afterstroke is 15% which is 
similar to that in postoperative patients. 
 
A secondary concern is the potential to cause the post 
thrombotic syndrome,characterized by persistent pain and swelling , 
with or without ulceration.24 The incidence of this disorder approaches 
90% in patients with untreated symptomatic DVT. Although it is 
recognized that many patients who present with this syndrome have no 
history of clinical  
 
VTE [ the entire process having been clinically silent],25 the 
incidence after  untreated asymptomatic DVT is unknown. The long 
term incidence in patients with  symptomatic, treated proximal DVT is 
approximately 30%, however there are conflicting data as to whether 
it occurs in patients with adequately treated asymptomatic proximal 
DVT.26 27 
 
 
 
 
 
 
 
 
 
 
CLINICAL SIGNIFICANCE OF ASYMPTOMATIC 
BELOW KNEE DVT AFTER STROKE: 
 
A major concern in patients with untreated below knee DVT  is 
the 20% risk of proximal extension,28 a subgroup that cannot be 
predicted accurately on clinical grounds. Clinical PE can however 
occur even in the absence of propagation and routine VQ scanning 
demonstrate silent PE in up to one third of patients who have isolated 
below knee DVT.29 30  
 
Although PE arising from below knee DVT are more likely to 
be small and asymptomatic and therefore less likely to be life 
threatening than those associated with proximal DVT ,31 32  the risk of 
fatal PE attributable to unteated, non propagating below knee DVT 
has not yet been defined. Symptomatic, isolated, below knee DVT 
may cause the post thrombotic syndrome,32but it is unclear whether 
this entity is a sequela in asymptomatic cases. 
 
 
 
INCIDENCE OF PULMONARY EMBOLISM AFTER 
STROKE: 
  
The incidence of PE reported in the absence of  heparin 
prophylaxis has varied considerably, depending on  the methodology 
of  the studies. In the international Stroke Trial [IST] the incidence 
was 0.8% at 2 weeks.33 Similarly, in a retrospective study of 607 
patients who had acute stroke,PE was reported in 1 % during the 
period of hospitalization.34  
 
However prospective studies that focused specifically on 
venous thromboembolic complications reported incidences of 10% to 
13%.35 
 
The risk of PE also extends to rehabilitation phase. In a 
retrospective study of 363 patients who did not receive heparin 
prophylaxis and entered rehabilitation unit 4 weeks after stroke 4% 
developed PE.36 
 
Only one small study prospectively screened for PE and found 
evidence of PE in 39%. Autopsy studies show that half of the patients 
who die in hospital after first 48 hours post stroke have evidence of 
PE, 37which suggest  that pulmonary emboli are often subclinical 
and/or unrecognized after acute   stroke. 
 
MORBIDITY AND MORTALITY DUE TO PE AFTER 
ACUTE STROKE: 
PE account for 13 to 25% of early deaths after stroke.38 – 40  Although 
they may occur as early as day 3 fatal emboli are unusual in the first 
week and are most frequent between second and fourth weeks , when 
they are the most common cause of death. Those more severely 
disabled are most likely to be affected, but PE may also occur in 
ambulatory patients. 
 
The mortality attributed to untreated  PE in unselected 
hospitalized patients is approximately 30%.41 However PE in stroke 
patients may have a higher mortality than that in other clinical 
settings. In one series of stroke patients half of the clinical PE 
presented as sudden death.42 The morbidity associated with non lethal  
PE should not be overlooked , this may manifest primarily as impaired 
cardiorespiratory reserve adversely affecting rehabilitation and 
potentially influencing functional outcome.43 
 
 
 
 
 
DIFFICULTIES IN DIAGNOSIS OF SYMPTOMATIC  
PE AFTER ACUTE STROKE: 
                  
The signs and symptoms of PE are notoriously non specific and   
both misdiagnosis and under diagnosis are well documented , more 
commonly  in the elderly. A number of factors make diagnosis even 
more difficult in post stroke patients, a group in whom ante mortem 
diagnosis is especially poor. Patients may not complain of symptoms 
because of dysphagia, cognitive impairment or mental obtundation.44  
 
In addition pneumonia , the illness for which PE is most often 
mistaken 45  is also common after stroke. Indeed, pneumonia and PE 
can commonly occur together, but the possibility of coexistent PE in a 
patient with strong clinical evidence of pneumonia is rarely 
considered. Subtle  clinical signs of PE like mild increase in 
respiratory rate are overlooked easily. 
 
Stroke patients with subclinical PE will usually undergo VQ 
scanning as the imaging  modality of first choice. The importance of  
integrating this information with an assessment of the clinical 
probability of  PE, either derived subjectively or by using scoring 
systems, has been stressed.46 
SUBCLINICAL VENOUSTHROMBOEMBOLISM: 
 
               
Clinically manifested disease represents the tip of the 
thromboembolism iceberg. Screening studies in both stroke  and post  
operative patients , together with the low incidence of symptomatic 
proximal DVT in patients with PE, demonstrate that the majority of 
DVTs are asymptomatic. Screening patients with symptomatic 
proximal DVT  without clinical evidence of PE reveals evidence of 
subclinical PE in up to half. 47 Furthermore,VQ scanning in 
predominately asymptomatic post operative patients reveal PE in 12% 
to 18%.48-50 Clearly only small proportion of pulmonary emboli 
produce symptoms.  
 
PATHOGENESIS  OF DVT: 
    
VIRCHOWS TRIAD: 
                                     
                                    
 
 
 
 
 
 
 
 
 
 
 
 
 
ENDOTHELIAL INJURY: 
                  
Mechanical venous injury clearly plays a role in thrombosis 
associated with direct venous trauma. The potential role of 
biochemical injury to venous endothelium has only lately become 
apparent.  
 
The normal venous endothelium is antithrombotic,producing 
PGI2, glycosaminoglycan co-factors of antithrombin, thrombomodulin 
and tissue type plasminogen activator[t-PA].50 However endothelium 
may become prothrombotic under some conditions producing  tissue 
factor, vWF and fibronectin .It is conceivable that some thrombotic 
risk factors act through production of a procoagulant endothelium. 
Microscopic changes  in the endothelial surface associated with 
STASIS
ENDOTHELIAL 
INJURY 
HYPERCOAGULABLE 
STATES 
greater endothelial permeability and leucocyte adhesion have been 
demonstrated in response to distant injury.  
 
Induction of procoagulant activity, suppression of anticoagulant 
mechanisms and exposure of neutrophil rceptor ligands may 
accompany such endothelial perturbation.51 
                                   
Associated inflammatory cells may be capable of both initiating 
and amplifying thrombosis. The importance of cytokine – mediated 
expression of tissue factor procoagulant activity under clinical 
conditions is unknown, but both IL-1 and TNF may induce fibrin 
deposition through a combination of endothelial procoagulant 
expression and  fibrinolytic depression.52 In such situations, Virchows’ 
concept of venous injury may be more important at the molecular 
level than macroscopic level. 
 
 
STASIS: 
           
Regardless of etiology, most venous thrombi originate in areas 
of low blood flow, either in soleal veins of the calf or behind valve 
pockets. Further more many risk factors of DVT are associated with 
immobilization and slow venous flow, and several mechanisms have 
been advanced to explain the role of stasis in thrombogenesis:  
 
 
1.    In comparison to pulsatile flow, static streamline flow is 
associated with profound hypoxia at the depths of venous valve cusps 
and may induce endothelial injury 53. The effects of hypoxia in 
cultured endothelial cells have been noted to include stimulation of 
cytokine production and leucocyte adhesion molecule expression. 
2. Furthermore, stasis allows accumulation of activated  
coagulation factors and consumption of inhibitors at sites prone for 
thrombosis. 
 
Stasis in large veins is particularly  important ,because the low 
surface to volume ratio may prevent interaction with endothelial 
inhibitory pathways, particularly the endothelium bound 
thrombomodulin- protein C system.52 
          
Despite these observations ,there is little evidence that stasis can  
activate coagulation in isolation, stasis appears to be an inadequate 
stimulus for  thrombosis. 
 
HYPERCOAGULABLE STATES: 
                     
 
Activation of  coagulation appears to be critical in the 
pathogenesis of DVT. The coagulation cascade functions through 
serial activation of zymogens in the intrinsic and tissue factor 
pathways , with the ultimate generation of thrombin by pro-
thrombinase complex. Anti thrombin and the thrombomodulin – 
protein C systems are the primary inhibitors of coagulation , whereas 
the fibrinolytic system serves to further limit fibrin deposition. 
Although  hemostatic system is continuously active, thrombus 
formation is ordinarily confined to sites of local injury by a precise 
balance between activators and inhibitors of coagulation and 
fibrinolysis. A prethrombotic state may result  either from imbalances 
in the regulatory and inhibitory systems or from activation exceeding 
antithrombotic capacity. 
              
Ordinarily activated coagulation factors are rapidly cleared from 
the circulation. When localized in regions of stasis , however, the 
coagulation cascade allows activated factors to rapidly amplify the 
thrombotic stimulus, leading to platelet aggregation and fibrin 
formation.54 
           
 
DVT thus appears to be a multi factorial phenomenon , with 
convergence of several pathologic factors often required to produce a 
thrombotic event. 
 
EARLY COURSE: 
             
The factors contributing to clinically important thrombosis have 
been most thoroughly evaluated in the valve pockets of lower 
extremity veins. In flow models, primary and secondary vortices are 
produce beyond the valve cusps, which tend to trap red cells in a low 
shear field near the apex of the cusp.55 The early nidus for  thrombus 
formation is  likely to  consist of RBC aggregates forming within these 
eddies; however these aggregates are probably transient until 
stabilized by fibrin in the setting of locally activated coagulation. 
         
Once formed in the valve pocket, early thrombi may become 
adherent to endothelium near the apex of the valve cusp. These valve 
pocket thrombi appear to form on structurally normal endothelium and 
largely to spare the valve cusp. Laminated appositional growth may 
then occur outward from the apex of the cusp, with propagation 
beyond the valve pocket probably depending on the relative balance 
between activated coagulation and thrombolysis. Once luminal flow is 
disturbed prograde and retrograde propagation may occur. 
 
Clinical symptoms, present in a minority of hospitalized 
patients, develop only when a sufficient fraction of venous flow is 
occluded. If present, such symptoms develop 24 – 36 hours after the 
first pearance of thrombus detectable by radioactive iodine- fibrinogen 
[I 125] scanning.  
 
Early thrombi may fail to propagate with evidence of aborted 
thrombi appearing as endothelialised fibrin fragments within the valve 
pockets. A significant number of early thrombi spontaneously resolve 
after serial I-125 fibrinogen scanning.56  
 
RISK FACTORS  FOR VTE: 
 
1. Surgery 
 
2. Trauma[major or lower extremities] 
 
3. Immobility 
 
4. Malignancy 
 
5. Cancer therapy[hormonal, chemotherapy or 
radiotherapy] 
 
6. Previous VTE 
 
7. Lactation 
 
8. Pregnancy and post partum period 
 
9. Estrogen containing hormone replacement therapy or 
oral contraceptives 
 
10. Selective estrogen receptor modulators 
 
11. Acute medical illness 
 
12. Heart or respiratory failure 
 
13. Inflammatory bowel disease 
 
14. Nephrotic syndrome  
 
15. Myeloproliferative disorders 
 
16. Paroxysmal nocturnal hemoglobinuria 
 
                       17. Obesity 
  
  18. Smoking  
 
  19.Varicose veins 
 
  20. Central venous catheterization 
 
  21. Inherited or acquired thrombophlebitis 
 
 
SYMPTOMS  OF  DVT: 
 
Many patients are asymptomatic; however , the history may 
include the following,57 
 
• Edema , principally unilateral , is the most specific  
symptom. Massive edema with cyanosis and  ischemia [ 
phlegmasia       cerulea dolens] is rare. 
 
• Leg pain occurs in 50%, but this is non- specific.  Pain 
can occur on dorsiflexion of foot [Homans ‘ sign]. 
 
• Tenderness occurs in 75% patients. The pain  and 
tenderness associated with DVT does not usually 
correlate with the size, location or extent of thrombus. 
 
• Clinical signs and symptoms of PE as the primary 
manifestation occur in 10% pf patients with  confirmed 
DVT. 
 
• Warmth and erythema of skin can be present over the 
area of thrombosis. 
 
SIGNS OF DVT : 
 
• Edema, principally unilateral 
 
• Tenderness , if present, is usually confined to the calf 
muscles or over the course of deep veins in the thigh 
 
• Pain and /or tenderness away from these areas is not 
consistent with venous thrombosis and usually indicates 
other diagnosis. 
 
• HOMANS’ SIGN : discomfort in the calf muscles on 
forced dorsiflexion of the foot with the knee flexed at 
30*. However this sign is present in less than one third of 
patients with confirmed DVT. 
 
• BANCROFT’S SIGN:tenderness on antero posterior, 
but not on lateral compression of the  calf. 
 
• LOUVEL SIGN: worsening of pain along the course of 
thrombotic vein on coughing or sneezing. 
 
• LOWENBERG SIGN after inflation of 
sphygmomanometer cuff around each calf, pain is 
experienced in the  affected calf at a lower  pressure than 
in the unaffected one. 
 
• Venous distension and prominence of the subcutaneous 
veins. Superficial thrombophlebitisis characterized by the 
finding of a palpable , indurated , cord-like, tender 
subcutaneous venous segment . Patients with superficial 
thrombohlebitis without coexisting varicose veins and no 
other obvious etiology are at high risk because associated 
DVT is found in 40% of these patients. 
 
• Fever : patients may usually have low grade fever 
 
• Phlegmasia cerulean dolens:  Patients with venous 
thrombosis may have variable discolouration of the lower 
extremity.the most common abnormal hue is reddish 
purple from venous engorgement and obstruction. In rare 
cases , the leg iscyanotic from massive ileofemoral 
obstruction. Petechiae are usually present. 
 
• Phlegmasia alba dolens: painful white inflammation was 
originally used to describe massive ileofemoral venous 
thrombosis and  associated arterial spasm.the affected 
extremity is often pale with poor or even absent pulses. 
The physical findings may suggest arterial obstruction , 
but the presence of swelling, petechiae and distended 
superficial veins points to DVT. 
 
• Clinical findings of PE: These are the primary 
manifestation in 10% of patients with DVT . In patients 
with angiographically  proven PE , DVT is found in 45-
70%. In the vast majority of these patients DVT is 
clinically silent. 
 
 
 
METHODS OF SCREENING FOR DVT: 
 
 
The choice of screening tool for DVT is problematic, because it 
would have to be  non invasive, inexpensive and highly sensitive. 
 
 
DUPLEX ULTRASONOGRAPHY: 
 
It is the most widely used diagnostic test now for acute DVT. 
Duplex  scanning is non invasive, widely available and portable with 
minimal complications. Evaluation of lower extremities includes an 
assessment of venous compressibility, intra luminal echoes, venous 
flow characteristics and luminal colour filling. Among these venous 
compressibility is the most widely used and objective criterion for the 
diagnosis of DVT.58 59 Incompressibility has excellent sensitivity and 
specificity for the detection of proximal DVT. Although compression  
ultrasonography appears superior to standardized doppler 
ultrasonography,incompressibility used in combination with the 
absence of phasic flow and visible thrombus can achieve a sensitivity 
of 95% and specificity of 83% 
 
Limitations: 
       
Adequate evaluation of tibial and peroneal veins may be 
impeded  by large calf size , edema or operator inexperience. Difficult 
compressibility and musculoskeletal structures may similarly limit  
evaluation of  iliac, superficial femoral  and upper extremity veins. 
However the use of colour flow Doppler significantly improves the 
accuracy of detecting isolated calf vein thrombosis. 
       
The utility of the technique for detecting asymptomatic below 
knee DVT after stroke has not specifically been evaluated . 
 
 
RADIOLABELLED FIBRINOGEN UPTAKE: 
 
 
Fibrinogen uptake radionuclide scanning was extensively used 
in1960s. It is more sensitive for DVTs in calf than in the thighs. But it 
has risk of transmission of infection with injected fibrinogen and also 
gives false positive results and hence not used widely now.57 
 
 
IMPEDANCE PLETHYSMOGRAPHY [IPG] : 
           
 
IPG is a sensitive method for evaluating the rate of venous 
return from lower extremities. This method detects increased venous 
outflow resistance in the deep veins of proximal lower extremities. It 
is safe, non invasive, rapid, inexpensive, has no radiation hazard and 
can diagnose symptomatic proximal DVT. Limitations include: 
operator dependent and cannot diagnose asymptomatic proximal DVT  
and non obstructing thrombi. 
 
 
D- dimer ASSAY: 
 
 
D- dimers are products of  the degradation of cross linked fibrin 
by plasmin. D – dimers level in blood  reflect the presence of 
intravascular  fibrin and are sensitive for diagnosis of venous 
thromboembolism. When measured by ELISA , the reference standard 
the sensitivity for the diagnosis of DVT is as high as 96.8%. However  
it is also elevated in DIC, malignancy, postoperative states, pre 
eclampsia, infection and trauma. Owing to low specificity  and 
positive predictive value, a positive D-dimer assay requires  
confirmatory testing.57 
 
 
FIBRINOGEN 
 
                                               FRAGMENTS 
X,Y,D,E 
 
THROMBIN 
 
 
SOLUBLE FIBRIN 
 
Factor XIII 
calcium 
 
 
CROSSLINKED FIBRIN             X- 
OLIGOMERS     
                                                                D-DIMERS  
 
plasmin 
plasmin 
D-dimers may have a useful role in identifying the subgroup of 
patients who need targeted screening but cannot be extrapolated to 
acute stroke  as non lacunar ischemic stroke   patients have increased 
D- dimer level and it falls to baseline after 30 days. Further studies are 
required to examine the utility of D – dimmer as a screening test for 
DVT in stroke.,60,61 
 
 
VENOGRAPHY:    
 
 
Ascending venography has been the gold standard confirmatory 
test for acute DVT. Not used frequently  now as it is invasive , 
contrast agents can be painful or they may extravasate into tissues and 
results in skin necrosis. They are also  irritating to the venous 
endothelium and may initiate thrombosis in 1.3 to 9% of patients.  
Cannulation of vein also requires expertise.   Cannot be done urgently. 
57  
 
 
RADIO ISOTOPE VENOGRAPHY:  
                           
Tc- 99  labelled RBCs or macro aggregated albumin can be 
used to detect DVT. It can be performed in conjunction with lung 
scanning. Scintigraphy using autologous labeled platelets can detect 
active DVT sites that are not readily evaluated by ultrasonography.57 
 
Limitations: 
     
 1. It does not provide direct information on cause of DVT     
 2. Unreliable in calf due to presence of multiple  vessels     
 3. Cannot distinguish intrinsic from extrinsic compression     
 4.Accuracy decreases in patients with previous DVT or congenital  
    duplication of deep venous system above the knee. 
 
 
CT VENOGRAPHY:  
       
 
Indirect venography is performed in spiral CT by volumetric 
acquisition from upper abdomen to popliteal fossa. Combined CT 
venography and pulmonary angiography is a single examination that  
combines multidetector CT pulmonary angiography and CT 
venography of the abdomen, pelvis and lower extremities.57 
 
Disadvantages: expensive, not portable and needs a contrast bolus  
 
comparable to angiogram.57 
 
 
MAGNETIC RESONANCE IMAGING: 
 
             
MRI is non  invasive  and allows simultaneous imaging in both 
lower limbs. In addition pelvic veins and IVC thromboses are 
accurately identified. MR venography compares favorably with 
contrast venography for the  diagnosis of symptomatic  proximal DVT 
but has not been evaluated for asymptomatic DVT. MR direct 
thrombus imaging has shown excellent sensitivity and specificity for 
the diagnosis of symptomatic  above and below knee DVT. This 
technique allows direct visualization of thrombi so that equally 
favorable  results might be expected in asymptomatic patients.57 
 
PRETEST PROBABILITY OF DVT: 
 
The WELLS  clinical prediction score provides a reliable 
estimate of the pretest probability of DVT 
 
CLINICAL PARAMETER SCORE 
Active cancer[treatment ongoing or within previous 6 months]     1 
Paralysis, paresis of lower extremity     1 
Recently bedridden for more than 3 days or surgery within 4 weeks     1 
Localized tenderness along deep venous system     1 
Entire leg swelling     1 
Calf swelling >3 cm compared to asymptomatic leg     1 
Pitting edema     1 
Collateral superficial veins     1 
Alternative diagnosis as likely or greater than DVT    - 2 
 
 
LOW RISK: 0 points 
 
MODERATE RISK: 1-2 points 
 
HIGH RISK : > 3 points 
 
PROPHYLAXIS FOR DVT: 
  
FEATURES OF IDEAL PROPHYLACTIC METHOD: 
 
 
• Effective 
 
• Safe 
 
• Good compliance with patient , nurses and  
physicians 
 
• Ease of administration 
 
• No need for lab monitoring 
 
• Cost effective  
 
 
 
SPECIFIC PROPHYLACTIC METHODS: 
 
Intermittent leg compression: 
 
The use of intermittent pneumatic leg compression prevents 
Venous thrombosis by enhancing blood flow in deep veins of the legs 
,there by avoiding venous stasis. It also raises blood fibrinolytic 
activity, which may contribute to its anti – thrombotic property. 
Intermittent pneumatic compressions is virtually free of significant 
side effects and offers a valuable alternative in patients who have a 
high risk of bleeding. 
 
 
 
 
 
 
Limitations: 
 
Poor compliance 
 
The rate of pressure rise and maximum pressure applied  to 
various part of the leg  were less than anticipated most of the time in 
patients undergoing intermittent pneumatic compression. 
 
 
Graduated compression stockings: 
                
Graduated compression stockings increase the velocity of  
venous blood flow . it is by no means clear how graduated 
compression stockings achieve a thromboprophylactic effect. 
 
Advantages:  simple, safe and moderately effective 
 
Contraindication : peripheral vascular disease. 
 
 
Their use is recommended in patients with low risk for 
thromboembolism and as an adjunct in  those with medium or high 
risk. 
 
 
Low dose unfractionated Heparin: 
 
 
Heparin  [UFH] molecules contain a unique pentasaccharide 
sequence that binds to antithrombin. Once bound to UFH the natural 
anticoagulant effect of antithrombin is potentiated , resulting in 
accelerated binding  and inactivation of serine proteases such as factor 
xa and thrombin.54 
               
The duration of initial  therapy with heparin has been reduced to 
five days to minimize hospital stay . The combination of heparin with 
warfarin is routinely recommended for prophylaxis of 
thromboembolism. Treatment with heparin requires regular 
monitoring of aPTT levels and aPTT value of 1.5 times the mean of 
control value  or upper limit of normal range is maintained. 
                         
                               
Low molecular weight Heparins: 
 
 
LMWHs are derived from enzymatic or chemical cleavage of  
UFH. They have limited antithrombin activity compared to anti factor 
xa activity. 
 
Advantage : Superior bioavailability, limited non specific 
binding and non dose dependant half life facilitate once or twice daily 
administration. 
 
No need for lab monitoring. 
 
LMWHs are cleared by renal mechanisms therefore multiday usage in  
 
patients with renal insufficiency should be avoided.54 
          
In randomized control trials comparing LMWHs with low dose 
unfractionated heparin, the LMWHs given once or twice daily have 
been   shown to be as effective or more in preventing thrombosis 
 
 
ORAL ANTICOAGULANTS: 
 
 
COUMARIN DERIVATIVES: 
                        
 
Warfarin inhibits vitamin k epoxide reductase and vitamin k 
reductase, thus inhibiting gamma decarboxylation of select glutamic 
acid residues in the N- terminus of prothrombin, factor  VII , IX and X 
, Protein C and S. This leads to synthesis of hypo functional 
coagulation proteins that are unable to bind to cellular surfaces to 
mediate coagulation reactions.The half life of warfarin in plasma is 36 
Hrs. Heparin therapy should overlap Warfarin  at least for a period of 
at least 4 days initially. Warfarin dosage is influenced by body stores 
of vitamin k, liver function, co existing medical disorders presence or 
absence of cytochrome p 450 2C9 mutations.Initial dosing of  2.5 to 
7.5 mg/d is started to achieve INR of  2 to 3 and then chronic 
anticoagulation for 6 months continued and dose adjusted to maintain 
INR of 1.5 to 2. 
 
 
 
NEWER DRUGS: 
 
DIRECT THROMBIN INHIBITORS : 
 
Indications: 
 
1. The persistent prothrombotic tendency associated with HIT 
 
2. the presence of thrombus in HIT with thrombosis 
 
3. patients’ original indication for heparin therapy 
 
 
Some direct thrombin inhibitors available are Argatroban, 
Bivalirudin, Ximelagatran, Lepirudin. Ximelagatran is promising as a 
treatment of acute  VTE, chronic management of atrial fibrillation and 
prevention of VTE in high risk settings such as following surgery and 
HIT.54 
 
 
PENTASACCHARIDES: 
   
 
They cause selective indirect inhibition of factor X a. 
Fondaparinux is a synthetic pentasaccharide and it is primarily used 
for thrombo prophylaxis in surgery. Idraparinux is a long lasting penta  
saccharide with once daily using.54 
 
 
 
 
 
MATERIALS AND METHODOLOGY: 
 
PLACE OF STUDY: 
   
             Institute of Internal medicine 
             
             Madras Medical College and Government General Hospital 
              
             Chennai 03. 
 
 
STUDY DESIGN: 
 
                  Cross sectional – hospital based  prevalence study 
 
STUDY PERIOD: 
                  
                     The study was conducted for a period of 7 months from  
 
December 2006 to June 2007. 
 
ETHICAL APPROVAL: Obtained  
 
FINANCIAL SUPPORT: NIL 
 
CONFLICT OF INTEREST: NONE 
 
LIMITATIONS: 
 
1. small number of cases 
 
2. d- dimer assay was not done for comparison due to 
financial  restraints. 
 
 
INCLUSION CRITERIA: 
 
1. Patients with acute stroke of less than two weeks duration. 
2. Recovery of power from admission till the end of study period 
less than 3/5 
3. Patients with or without known history of diabetes mellitus, 
systemic hypertension. 
4. Patients with  risk  for accelerated atherogenesis such as 
smoking or alcoholism. 
 
  EXCLUSION CRITERIA: 
 
• Duration of stroke more than two weeks 
• Recovery of power from time of admission to screening 
for DVT is more than 3/5 
• Pregnancy 
• Patients on treatment with drugs like aspirin, OCPs or 
anticoagulants 
• Patients with underlying procoagulant states previously 
known 
• Patients with underlying connective tissue diseases. 
 
 
 
 
STUDY POPULATION: 
  
 
Out of 145 patients enrolled for the study after applying the 
exclusion criteria 50 patients were selected for duplex ultrasonography 
of lower limb venous system. 
 
METHODOLOGY: 
 
 
All  patients admitted with c/o acute stroke of  less than two 
weeks in our hospital, were screened preliminarily with a proforma to 
assess  the  presence of predisposing conditions of CVA  like diabetes, 
systemic hypertension, ischemic heart disease and valvular heart 
diseases. Also patients were specifically questioned on their 
medications which could affect coagulation as well as any history of 
addictions. Detailed physical examination was done. Basic 
investigations like CBC, Random blood sugar, Serum fasting lipid 
profile and ECG were taken for all patients included in the study. CT 
brain was also done. Evaluation of cardio vascular system with echo-
cardiography was done. 
 
The patients were examined and their improvement with 
regards to general physical condition, control of blood pressure and 
improvement in neurological status with special attention to recovery 
of tone and power was assessed daily. Signs and symptoms for 
development of DVT were specifically looked for. 
 
Patients with Diabetes, ischemic heart disease and other 
underlying diseases were treated for their respective diseases in 
addition to  receiving anti edema measures, antibiotics and anti ulcer 
drugs as well as aspirin in recommended dose for patients with 
ischemic stroke. 
 
Physiotherapy to the paralysed limb was started as early as day1 
of admission and patients and their care givers were encouraged to 
continue it all through their hospital stay. 
 
Patients with persistent hypotonia and power < 3/5 at the end of 
14 days were screened for the presence of DVT of the paralysed limb 
with ultra sound venous colour flow Doppler on day of admission and 
day 14  and the results documented. Patients who had developed DVT 
despite intensive physiotherapy were treated with leg elevation, 
graded compressive stockings and LMWHs. They were followed up 
during the entire course of hospital stay with repeated USG venous 
Doppler. 
STATISTICAL ANALYSIS 
 
Statistical analysis was carried for 50 subjects. Age, 
presence of diabetes, systemic hypertension, ischemic heart 
disease, smoking, and alcoholism in DVT positive and 
negative group were analyzed. The statistical significance 
calculated using chi-square test. 
 
 Statistical significance taken when p value < 0.05.Statistical 
analysis were carried out using standard formulae. Microsoft excel 
2003 and SPSS [statistical package for social sciences] version 13.0 
soft wares were used for data entry and analysis. 
 
 
 
 
 
 
 
 
 OBSERVATIONS: 
 
We included 50 patients with acute stroke in our study and all 
of them had venous Doppler done for lower limb venous system. 
 
Table 1: prevalence of DVT in acute stroke patients  
Total number of patients in whom venous 
doppler was done 
DVT positive  Percentage  
50 3 6% 
 
 
TABLE : 2 Patient characteristics 
Characteristics Present 
(No) 
 
% 
Absent 
(No) 
 
% 
DM 9 18 41 82 
SHT 15 30 35 70 
IHD 2 4 48 96 
SMOKING 22 44 28 56 
ALCOHOLISM 14 28 36 72 
 
 
  
TABLE : 3 CT findings: 
 
CT Number % 
Infarct       42    84 
Hemorrhage         8    16 
Total       50    100 
  
 
 
        TABLE: 4 Sex distribution  of DVT  
 
Sex  Number  DVT positive DVT negative 
Male      36      1    35 
Female      14     2    12 
Total     50     3    47  
 
 
  
TABLE :  5 Risk factor analysis in DVT positive patients  
5 a)DM Vs DVT 
 
DM 
 
DVT PRESENT 
 
DVT ABSENT 
 
TOTAL 
PRESENT 0 9 9 
ABSENT 3 38 41 
TOTAL 3 47 50 
 
P VALUE:0.40259   Odds’ ratio – 1.0789 , CI [0.990,1.176] 
 
5 b) SHT Vs DVT: 
 
SHT 
 
DVT PRESENT 
 
DVT ABSENT 
 
TOTAL 
PRESENT 0 15 15 
ABSENT 3 32 35 
TOTAL 3 47 50 
 
P VALUE: 0.24219  Odds’ ratio – 1.0938, CI [0.998,1.211] 
 
  
5 c) IHD Vs DVT 
 
IHD 
 
DVT PRESENT 
 
DVT ABSENT 
 
TOTAL 
PRESENT 0 2 2 
ABSENT 3 45 48 
TOTAL 3 47 50 
 
P VALUE: 0.71536, Odds’ ratio – 1.0666, CI [0.9915, 1.1475] 
 
 
5 d) SMOKING Vs DVT: 
 
SMOKING 
 
DVT PRESENT 
 
DVT ABSENT 
 
TOTAL 
PRESENT 1 21 22 
ABSENT 2 26 28 
TOTAL 3 47 50 
 
P VALUE: 0.7011, Odds’ ratio – 1.0279, CI [0.896,1.179] 
 5 e) ALCOHOL Vs DVT: 
  
ALCOHOL DVT PRESENT DVT ABSENT TOTAL 
PRESENT 1 13 14 
ABSENT 2 34 36 
TOTAL 3 47 50 
 
P VALUE: 0.83195, Odds’ ratio – 0.983, CI [ 0.833,1.160 ] 
 
 
In our study the prevalence of DVT in acute stroke was 
analysed by ultrasound venous Doppler of lower limbs.  The analysis 
of co morbid conditions like diabetes , systemic hypertension, 
ischemic heart disease, smoking and alcoholism were analysed to find 
out if there was any association between their presence and occurrence 
of DVT. In all these parameters compared within the group of DVT 
positive patients the   p value was more than 0.05 which is statistically 
insignificant. 
 The important observations noted in the study were: 
 
1.  The prevalence of DVT was found in 6% of Stroke Patients. 
 
2. The prevalence of DVT was found more commonly in women than 
in men 
 
3. The occurrence of DVT in acute stroke is independent of the 
presence of co morbid conditions like diabetes, systemic hypertension, 
ischemic heart disease and high risk behaviors like smoking and 
alcoholism. 
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DISCUSSION: 
 
The prevalence of DVT in patients with acute stroke admitted 
into government general hospital is found to be 6% as against a 
prevalence of 60% reported in western literature. The exact cause for 
this discrepancy is not known but there does seem to be difference in 
occurrence of DVT in different ethnic groups as revealed by studies. 
The incidence of post op DVT in Europe is twice that of North 
America, similarly autopsy series showed prevalence of thrombo 
embolism is 40.6% in Boston and 13.9% in Kyushu, Japan. This may 
probably be explained due to regional variation in underlying medical 
conditions or true variation in genetic and environmental factors. 
 
There are also studies published reporting increases in incidence 
of DVT with age. In elderly probably there is an increase in number of 
thrombotic risk factors or there exist an acquired thrombotic state, 
with  anatomic changes in soleal veins with more pronounced stasis in 
valve pockets. 
 
 
 
 
The prevalence of DVT both asymptomatic and symptomatic in 
acute stroke patients in our hospital was only 6% and the exact 
occurrence of pulmonary embolism in these patients is not known. 
                                    
Though there are widely conducted trials in the west on routine 
prophylaxis of DVT with anticoagulants as early as day 2 of stroke, 
such studies are not available in Indian population and the data from 
west cannot be extrapolated to our population as the prevalence of 
DVT is found to be very low and majority are asymptomatic. 
 
The mortality and morbidity  rate of patients with acute stroke 
in our study population was not significantly affected by withholding 
routine anticoagulation therapy. 
 
Risk associated with anticoagulation in acute stroke should also 
be taken into consideration.   In the IST , treatment with low dose 
unfractionated heparin [ 5000 U s.c. twice daily] significantly reduced 
death and recurrent stroke at 14 days from 12 to 10.8%, a benefit 
attributable  to decreased risk of recurrent ischemic stroke as PE was 
not significantly reduced. There was also increased risk of 
hemorrhagic transformation and extra cranial bleeds. 
 
The balance of risks might therefore favor initiation of 
anticoagulation treatment in  established venous thrombo embolism 
after stroke, where the risks of untreated VTE is high and mortality is 
proven to be reduced with anticoagulation therapy. The routine 
prophylaxis for patients with asymptomatic below knee DVT is still 
controversial and more studies are recommended before the benefits 
could be conclusively established. 
   
Physiotherapy and mechanical anticoagulation with graded 
compressive stockings can be considered as the initial line of 
prophylaxis as there is no increased risk of bleeding. The sensitivity of  
duplex sonography in detecting DVT is 97% and it is a simple, non 
invasive reliable tool which can be done as early as day two and serial 
follow up can be done as and when required. The treatment of DVT 
can be initiated as soon as it is detected as the risk of PE is only by 
three to four weeks after stroke. This strategy helps in minimizing  
unwanted anticoagulation in stroke patients and risk of hemorrhagic 
transformation. 
 
Further more, majority of early  thrombi formed resolve 
spontaneously when followed up with I 125fibrinogen screening. Thus 
the role of routine anticoagulation in stroke is still inconclusive and 
controversial. 
 
 
 
DIAGNOSTIC PATHWAY FOR DVT : 
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CONCLUSIONS: 
 
                                 
1.The prevalence of DVT in acute stroke patients in our hospital 
group was 6% which is significantly less than that observed in western 
population. 
2.Duplex USG is a useful tool which can be used as a screening 
tool for early diagnosis of DVT. 
3.DVT occurs more commonly in paralysed limd than non 
paralysed limb. 
4.VTE is a preventable cause of morbidity and mortality in 
stroke patients and there is a need for more anticipatory approach in 
diagnosis. 
5.The presence of comorbid conditions like diabetes, SHT,IHD, 
smoking and alcoholism does not affect the occurrence of DVT in 
acute stroke  thus it is an independent contributor to morbidity and 
mortality in stroke  patients. 
6.The use of routine anticoagulation in all stroke patients in our 
population requires further large scale trials before their benefits could 
be conclusively proven. 
 
 
 
PROFORMA: 
 
Name:                                                        I.p. no: 
 
Age:                                                            Sex 
 
D.O.A:                                                       D.O.D: 
 
Onset and duration of illness: 
 
Past h/o: DM/SHT/IHD 
 
Drugs: ASA/Anticoagulants/OCPs 
 
Personal h/o: smoker/ alcoholism 
 
G.E: 
      
                      P/I/Cy/Cl/PE/LN 
 
                      PR:                                           B.P. 
  
                     CVS: 
 
                      RS: 
 
                      P/A: 
 
                    CNS: 
 
                         Higher functions: 
 
                         Cranial nerves: 
                     
 
 
 
 
 
 Motor system examination: 
 
                                                               R                                 L 
 
                            Tone           UL 
              
                                               LL 
 
                           Power         UL 
 
                                              LL 
 
 
                            DTR:        UL 
 
                                             LL 
 
                             Plantar  
 
Sensory system examination:  
 
Investigations:  
 
          CBC:                                             RFT: 
                      
          RBS:                                             S.fasting lipid profile : 
 
          ECG:                                             CT brain: 
 
          ECHO:                                           
       
          USG venous Doppler  both lower limbs :      
 
MASTER CHART 
Sl.no Name Age Sex ECHO CT DOPPLER DM SHT IHD DRUGS smoker
1 jayaraman 55 m N INF N N Y N N Y 
2 palani 68 m N INF N Y N N N Y 
3 masthan 45 m LVH HE N N N N N Y 
4 nageshwarao 33 m N INF N N N N N Y 
5 shantharao 54 m N INF N N N N N Y 
6 nandan 50 m N INF N N N N N Y 
7 suresh1 27 m N INF N N N N N N 
8 ammavasi 54 m N INF N N Y N N Y 
9 balakrishnan 55 m N INF N N N N N N 
10 ravi 38 m THR LA INF N n N N Y Y 
11 libinjohn 46 m N INF N Y N N Y Y 
12 suresh2 25 m N INF N N N N N N 
13 srinivasan 80 m N INF N Y N N N N 
14 gopal 55 m N INF N N Y N N Y 
15 elumalai 60 m N INF N N N N N Y 
16 kanniappan 70 m N INF N N N N N N 
17 rajendran 35 m N INF N N N N N N 
18 venkatesan 54 m LVH INF N N Y N Y Y 
19 govindaraj 53 m N HE N N Y N Y Y 
20 sekar 45 m N INF N N N N N Y 
21 lillyvasantha 58 f N INF N Y N N N N 
22 rajendran 50 m N INF N N N N N N 
23 lakshmiammal 70 f N INF N Y N N N N 
24 duraikannammal 55 f LVH INF N Y Y N Y N 
25 ganesan1 45 m N INF N Y Y N N Y 
Sl.no Name Age Sex ECHO CT DOPPLER DM SHT IHD DRUGS smoker
26 duraisamy 55 m N INF N N N N N N 
27 shanthi 45 f N INF LLDVT N N N N N 
28 gopal 62 m N INF N N Y N N Y 
29 ganesan2 55 m LVH INF N N Y N N Y 
30 chandran 58 m N HE N Y Y N N N 
31 jayalakshmi 61 f N HE N N Y N N N 
32 egathammal 85 f N INF N N N N N N 
33 jayalakshmi 61 f N HE N N Y N N N 
34 devi 23 f N INF N N N N N N 
35 pacchaiammal 70 f LVH INF N N N Y Y N 
36 jegatha 45 f N INF N Y N N N N 
37 kasi 40 m N INF N N N N N N 
38 subramani 60 m N INF N N N N N N 
39 venkatraman 64 m N HE N N N Y N N 
40 vijayalakshmi 64 f N INF LLDVT N N N N N 
41 santhalingam 54 m LVH INF N N Y N N Y 
42 devaraj 55 m N INF N N N N N N 
43 pattamal 60 m NOT HE N N Y N N N 
44 selvam 31 m N INF N N N N N Y 
45 kathamuthu 55 m N HE N N N N N Y 
46 parvathy 45 f N INF N N N N N N 
47 kubarna 33 m N INF RLDVT N N N N Y 
48 valliammal 70 f LVH INF N N Y N N N 
49 muniammal 61 f N INF N N N N N N 
50 veerabadhran 55 m N INF N N N N N Y 
 
 
ABBREVIATIONS:                 
 
DVT - Deep vein thrombosis   
 
PE     - Pulmonary embolism 
 
USG   - Ultrasound 
 
VTE   - Venous thrombo embolism 
 
DM    -Diabetes mellitus   
 
SHT   - Systemic hypertension 
 
IHD   -  Ischemic heart disease 
 
ASA   - Aspirin  
 
LMWH- Low molecular weight heparins 
 
CVA - Cerebro vascular accident 
 
HIT    - Heparin induced thrombocytopenia 
 
IST    - International stroke trial 
 
UFH  - Unfractionated heparin 
 
aPTT  - Activated partial thromboplastin 
 
Tc 99 – technetium 
 
I-125 – Iodine 125  
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